1 Durham VA Medical Center, Durham, North Carolina.
J Manag Care Spec Pharm. 2016 Sep;22(9):1051-61. doi: 10.18553/jmcp.2016.22.9.1051.
Several cost analysis studies have been conducted looking at clinical and economic outcomes associated with clinical pharmacist services in a variety of health care settings. However, there is a paucity of data regarding the economic impact of clinical pharmacist involvement in formulary management at the hospital level.
To evaluate economic outcomes of a pharmacist-adjudicated formulary management consult service in a Veterans Affairs (VA) medical center offering outpatient and inpatient services.
This VA medical center uses a pharmacist-adjudicated formulary management system for review of restricted drug consults. A retrospective review of electronic medical records was conducted to identify restricted drug consults at this institution between January 1, 2014, and March 31, 2014. Only restricted drug consults that were not approved were included for evaluation in order to best characterize the effects of formulary interventions by pharmacists. Economic outcomes were determined as direct cost savings by comparing the cost of requested drug with the recommended drug and accounting for the cost of pharmacist review. Characteristics of consults that were not approved and pharmacist rationale were also evaluated.
Of 1,802 restricted drug consults adjudicated by a pharmacist during the study period, 198 consults in 190 individual patients met criteria for inclusion and were evaluated. The most commonly requested indications were dyslipidemia, pain, and diabetes, while the most commonly requested drugs were rosuvastatin, insulin pens, tamsulosin, varenicline, ezetimibe, and rivaroxaban. The majority of consults were requested for outpatient use. Total cost savings among 195 evaluable consults was $420,324.05, while mean cost savings per consult was $2,229.43 (range: -$3,009.27-$65,982.36). The highest cost savings were seen with outpatient use.
A pharmacist-adjudicated formulary consult service in a VA medical center was associated with a substantial cost savings after adjustment for cost of pharmacist review. Future research should assess clinical outcomes associated with a restrictive formulary management system.
No outside funding supported this study. None of the authors report any financial interests or potential conflict of interest with regard to this work. Study concept and design were created by all authors. Data were collected and interpreted by Britt, with input from all authors. The manuscript was written by Britt and revised by all authors.
已有多项成本分析研究着眼于临床和经济结果,评估了各种医疗环境下临床药师服务的临床和经济效果。然而,关于临床药师参与医院层面的处方集管理对经济影响的数据却很少。
评估退伍军人事务部(VA)医疗中心药剂师参与审查限用药物处方集管理咨询服务的经济效果,该医疗中心提供门诊和住院服务。
该 VA 医疗中心使用药师审查的限用药物处方集管理系统来审查限制药物咨询。对该机构 2014 年 1 月 1 日至 3 月 31 日期间的电子病历进行回顾性审查,以确定该机构的限制药物咨询。仅纳入未获得批准的限制药物咨询进行评估,以最佳描述药剂师处方集干预的效果。通过比较请求药物与推荐药物的成本并考虑药师审查成本,确定经济效果为直接成本节约。还评估了未获批准的咨询特征和药剂师的基本原理。
在研究期间,有 1802 次限制药物咨询由药师进行了裁决,其中 198 次咨询涉及 190 名患者,符合纳入标准并进行了评估。最常见的请求适应症为血脂异常、疼痛和糖尿病,而最常见的请求药物为瑞舒伐他汀、胰岛素笔、坦索罗辛、伐伦克林、依折麦布和利伐沙班。大多数咨询为门诊使用。在 195 次可评估咨询中,总节省成本为 420324.05 美元,每次咨询的平均节省成本为 2229.43 美元(范围:-3009.27 美元至 65982.36 美元)。门诊使用的节省成本最高。
退伍军人事务部医疗中心的药师裁决处方集咨询服务在调整药师审查成本后,与大量成本节约相关。未来的研究应评估限制性处方集管理系统相关的临床结果。
本研究无外部资金支持。作者均未报告与本工作相关的任何经济利益或潜在的利益冲突。所有作者均提出了研究概念和设计。数据由 Britt 收集和解释,并得到所有作者的输入。手稿由 Britt 撰写,所有作者修订。